Rohypnol (flunitrazepam) is prescribed for two conditions: insomnia and pre-surgical sedation. It is a powerful benzodiazepine sedative that has never been approved for medical use in the United States but remains legally prescribed in several European countries. Its reputation as a drug of abuse has overshadowed its legitimate medical role, but it is still used clinically in parts of the world.
Treating Severe Insomnia
The primary prescription use of Rohypnol is for insomnia. It works by enhancing the activity of a calming brain chemical called GABA, which slows down nerve signaling and produces sedation. At low doses, flunitrazepam acts as an anxiety reducer, muscle relaxant, and sleep inducer. The drug reaches its peak concentration in the blood within about 45 minutes of taking it, which makes it effective for people who have difficulty falling asleep.
The standard adult dose for insomnia is 0.5 to 1 mg taken at bedtime. In exceptional circumstances, a doctor may increase that to 2 mg. For elderly patients or those with other health conditions, the usual dose is 0.5 mg, with a maximum of 1 mg. Patients with organic brain changes are kept at no more than 0.5 mg. The drug has a long elimination half-life of 16 to 35 hours, meaning its sedative effects can linger well into the next day, which is one reason it requires careful dosing.
Pre-Anesthesia Sedation
Rohypnol’s second approved use is as a pre-anesthetic medication. In this role, it helps patients relax before surgery and assists in the induction and maintenance of general anesthesia. Its fast onset and strong sedative properties make it useful in hospital settings where controlled sedation is needed before a procedure begins. This use is managed entirely by anesthesiologists in clinical environments.
Where Rohypnol Is Legally Prescribed
Rohypnol has never been approved by the U.S. Food and Drug Administration, and it is not legally available for any medical purpose in the United States. The DEA does not schedule it as a controlled substance with accepted medical use domestically. Possessing, importing, or distributing it in the U.S. carries significant legal consequences.
Outside the U.S., flunitrazepam is authorized for medical use in several European countries. As of 2019, the European Medicines Agency listed it as nationally authorized in Germany, France, Italy, Austria, Greece, and Cyprus. In these countries, it is available by prescription and dispensed through pharmacies like other regulated sedatives. It has also been used in parts of Latin America and Asia, though availability varies.
Side Effects at Therapeutic Doses
Even when taken as prescribed, Rohypnol produces a notable range of side effects. The most commonly reported ones include excessive sweating, unsteady coordination, blurred vision, dry mouth, weakness, low body temperature, slowed breathing, and prolonged drowsiness that can persist into the following day. That long half-life means residual grogginess is common, particularly in older adults or those on higher doses.
The side effect that draws the most attention is anterograde amnesia, which is the inability to form new memories while the drug is active. At therapeutic doses, this can mean waking up with hazy or absent recall of the period between taking the pill and falling asleep. At higher doses, this amnesia becomes more pronounced and can extend to complete gaps in memory. Research has shown that flunitrazepam specifically impairs the brain’s ability to form new associations between events, which is why people under its influence may have no recollection of what happened to them. This property is central to why the drug has been misused.
Why It Became Known as a Date-Rape Drug
Rohypnol’s combination of rapid sedation, strong amnesia, and the fact that early formulations dissolved invisibly in liquids made it a tool for drug-facilitated sexual assault. The original white 2 mg tablets dissolved clear in drinks, making them virtually undetectable. In 1997, the manufacturer reformulated the tablets in response to these concerns. The new versions are smaller doses (0.5 mg and 1.0 mg), dull green on the outside with a blue core. When dropped into a light-colored drink, they release a blue dye intended to alert someone that their beverage has been tampered with.
This reformulation did not eliminate misuse entirely, but it made covert administration harder. The drug’s capacity to cause disinhibition at moderate doses can also contribute to impaired judgment, motor vehicle accidents, and vulnerability to violence or assault, even when taken voluntarily.
How It Compares to Other Sleep Medications
Rohypnol is roughly 10 times more potent than diazepam (Valium), which is why its therapeutic doses are measured in fractions of a milligram rather than the 5 to 10 mg range common for other benzodiazepines. Its mechanism is also more complex than many drugs in its class. While most benzodiazepines simply amplify GABA’s calming signal, flunitrazepam can act differently depending on which type of GABA receptor it binds to. On the most common receptor type, it enhances sedation as expected. On other receptor configurations, it can produce the opposite effect. This pharmacological complexity is one reason it remains a subject of scientific interest even as clinical use has narrowed.
In countries where it is prescribed, Rohypnol occupies a niche for patients with severe insomnia who have not responded to milder sleep aids. Its long duration of action, strong amnesia-producing properties, and high potential for dependence mean it is rarely a first-line treatment. Most prescribing guidelines recommend it only for short-term use.